Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, First-in-Human, Nested Bioavailability Study to Assess Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of FTX-101 After Subcutaneous Injection of FTX-101 in Healthy Male Subjects

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, First-in-Human, Nested Bioavailability Study to Assess Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of FTX-101 After Subcutaneous Injection of FTX-101 in Healthy Male Subjects

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FTX 101 (Primary) ; FTX 101 (Primary)
  • Indications Multiple sclerosis; Optic neuritis
  • Focus Adverse reactions; First in man
  • Sponsors Find Therapeutics

Most Recent Events

  • 18 Jun 2025 Status changed from recruiting to discontinued.
  • 27 Sep 2024 Status changed to recruiting.
  • 27 Aug 2024 According to Find Therapeutics media release, company announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for FTX-101 and company plans to initiate the trial in Q4 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top